Clinical Trial Update: Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alpelisib in combination with continued endocrine therapy after progression in HR-positive, HER2-negative, PIK3CA-mutant metastatic bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Pik3ca-mutant Metastatic Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)

Snippet

Sponsor: Marina N Sharifi | Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING